# Blackstone Life Sciences

> Blackstone Life Sciences is a VC fund backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 23
- Last investment: May 2026
- Lead investor: 70%
- Last updated: Aug 2026
- Website: https://www.blackstone.com/our-businesses/life-sciences

Blackstone Life Sciences is a VC fund in Cambridge focused on Biotechnology and Health Care. Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medicaltechnology industries to help meet this need.

## Contacts

5 contacts available for Blackstone Life Sciences. Shizune tracks 7 team members at Blackstone Life Sciences. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/blackstone-life-science?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 65% |
| Health Care | 12 | 52% |
| Therapeutics | 8 | 35% |
| Medical | 6 | 26% |
| Pharmaceutical | 5 | 22% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 8 | 35% |
| Series C | 3 | 13% |
| Series A | 2 | 9% |
| Series B | 2 | 9% |
| Series D | 1 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 70% |
| France | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Emmett Cunningham | Senior Managing Director | 2 | — |
| Joseph Dowling | Senior Managing Director and the Global Head of Blackstone Multi-Asset Investing | 1 | — |
| William Young | Senior Advisor | 6 | — |
| Evan Rachlin | Principal | 10 | https://shizune.co/investors/profile/evan-rachlin |
| Kurt Wheeler | Senior Managing Director | 12 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Apogee Therapeutics | Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance novel therapies to address patients’ needs. Based in San Francisco, California, Apogee Therapeutics was founded in 2022. | $1.3B | Post-IPO Debt | May 27, 2026 |  |
| Anagram Therapeutics | Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatmentburden in Progressive Pulmonary Disease and Malabsorption Syndromes. | $250M | Private Equity | May 07, 2026 |  |
| Anagram Therapeutics | Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatmentburden in Progressive Pulmonary Disease and Malabsorption Syndromes. | $250M | Private Equity | May 07, 2026 |  |
| Teva Pharmaceuticals | Teva Pharmaceuticals is a global leader in generics and bio pharmaceuticals, improving the lives of patients around the globe. | $400M | Private Equity | Mar 03, 2026 |  |
| GRIN Therapeutics | GRIN Therapeutics is a clinical-stage biotechnology company dedicated to developing precision therapeutics for serious pediatric neurodevelopmental disorders. | $140M | Series D | May 27, 2025 |  |
| AvenCell | Based on our deep science and focused on patients in need. | $112M | Series B | Oct 22, 2024 |  |
| Uniquity Bio | Uniquity Bio operates a drug development company. | $300M | Series A | May 15, 2024 |  |
| Uniquity Bio | Uniquity Bio operates a drug development company. | $300M | Series A | May 15, 2024 |  |
| Moderna | Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck. | $750M | Post-IPO Equity | Mar 27, 2024 |  |
| Amicus Therapeutics | Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatmentapproach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes. | $30M | Post-IPO Equity | Oct 02, 2023 |  |

10 of 23 investments shown.

## Co-investors
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 4 deals together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 2 deals together
- [Irving Investors](https://shizune.co/investors/profile/irving-investors) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Blackstone Life Sciences invest in?

Blackstone Life Sciences invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series C stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Blackstone Life Sciences?

Public channels for Blackstone Life Sciences include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Blackstone Life Sciences?

The team at Blackstone Life Sciences includes Emmett Cunningham (Senior Managing Director), Joseph Dowling (Senior Managing Director and the Global Head of Blackstone Multi-Asset Investing) and William Young (Senior Advisor), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co